Abivax’s stock reaction to positive phase 3 results in ulcerative colitis sharpened around a malignancy signal flagged by analysts, underscoring how safety interpretation can rapidly alter commercial expectations. The company reported topline efficacy from its ABTECT maintenance trial (obefazimod; NCT05535946), but shares fell after concerns over nine malignancies among 580 enrolled patients. Jefferies, Morgan Stanley, Truist Securities, and Wedbush all weighed in by adjusting price targets and, in at least one case, moving the rating toward a more cautious stance. The reported malignancy breakdown included squamous cell carcinoma cases across dose arms and placebo, with the analyst commentary focusing on the potential for an investor and label overhang. The episode reflects how late-stage safety nuance—especially cancer signals in maintenance settings—can dominate near-term valuation even when efficacy is positive.